- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT02518802
Pemetrexed Combined With Synchronous Gefitinib as Adjuvent Therapy in Patient With EGFR Mutant Lung Adenocarcinoma
Pemetrexed Disodium and Cisplatin Chemotherapy Combined With Synchronous Gefitinib vs Chemotherapy Alone as Adjuvent Therapy in Patient With Stage II-IIIA, Epidermal Growth Factor Receptor Mutant Expressing Lung Adenocarcinoma
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Adjuvant cisplatin-based chemotherapy is recommended for routine use in patients with stages IIA, IIB, and IIIA non-small cell lung cancer (NSCLC) after complete resection. Cisplatin and pemetrexed combination is the standard regimen for lung adenocarcinoma in adjuvant setting. The BR. 19 trial reported adjuvant gefitinib after complete resection of early stage NSCLC(stage IB 49%, II 38%, III 13%) did not confer disease free survival(DFS) or overall survival(OS) advantage in overall population. While the median gefitinib treatment time is only 4.8 months. There are only 76 patients with EGFR mutations included in this analysis. The study closed prematurely in 2005.
Activating somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor (EGFR) have been characterized in a subset of patients with advanced NSCLC.The EGFR mutation rate was 30% in Chinese NSCLC. Patients harboring these mutations in their tumors show excellent response to EGFR tyrosine kinase inhibitors (EGFR-TKIs). This randomized phase III trial is studying gefitinib and synchronous pemetrexed/cisplatin chenmotherapy to see how well it works compared to pemetrexed/cisplatin chenmotherapy alone in treating patients who have undergone surgery for stage II-IIIA(N1-N2) lung adenocarcinoma with EGFR activating mutation in Asian population.
Tipo de estudo
Inscrição (Antecipado)
Estágio
- Fase 3
Contactos e Locais
Contato de estudo
- Nome: Li Xiaofei, MD
- Número de telefone: +8629,84777436
- E-mail: lxfchest@fmmu.edu.cn
Estude backup de contato
- Nome: Yan Xiaolong, MD
- Número de telefone: +8629,84717558
- E-mail: yanxiaolong@fmmu.edu.cn
Locais de estudo
-
-
Shaanxi
-
Xi'an, Shaanxi, China, 710038
- Recrutamento
- Tangdu Hospital of the Fourth Millitary Medical University
-
Contato:
- Li Xiaofei, MD
- Número de telefone: +8629,84777436
- E-mail: lxfchest@fmmu.edu.cn
-
Contato:
- Yan Xiaolong, MD
- Número de telefone: +862984717558
- E-mail: yanxiaolong@fmmu.edu.cn
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Written informed consent provided.
- Males or females aged ≥18 years, < 70 years.
- Able to comply with the required protocol and follow-up procedures, and able to receive oral medications.
- Target population is completely resected pathological stage II-IIIA(N1-N2) NSCLC with EGFR exon 19 deletions and exon 21 L858R activating mutation.
- Patient who can start the investigational therapy within 3-6 weeks after the complete resection
- ECOG performance status 0-1.
- Life expectancy ≥12 weeks.
- Adequate hematological function: Absolute neutrophil count (ANC) ≥2.0 x 109/L, and Platelet count ≥100 x 109/L, and Hemoglobin ≥9 g/dL (may be transfused to maintain or exceed this level).
- Adequate liver function: Total bilirubin ≤ 1.5 x upper limit of normal (ULN), Aspartate aminotransferase (AST), alanine aminotransferase (ALT) ≤ 2.5 x ULN in subjects without liver metastases; ≤ 5 x ULN in subjects with liver metastases.
- Adequate renal function: Serum creatinine ≤ 1.25 x ULN, or ≥ 60 ml/min.
- Female subjects should not be pregnant or breast-feeding.
Exclusion Criteria:
- Known severe hypersensitivity to gefitinib or any of the excipients of this product.
- Known severe hypersensitivity to pre-medications required for treatment with cisplatin / vinorelbine doublet chemotherapy.
- Inability to comply with protocol or study procedures.
- A serious concomitant systemic disorder that, in the opinion of the investigator, would compromise the patient's ability to complete the study.
- A serious cardiac condition, such as myocardial infarction within 6 months, angina, or heart disease.
- Interstitial pneumonia.
- Patients with prior exposure to agents directed at the HER axis (e.g. erlotinib, gefitinib, cetuximab, trastuzumab).
- Patients with prior chemotherapy or therapy with systemic anti-tumour therapy (e.g. monoclonal antibody therapy).
- Patients with prior radiotherapy
- History of another malignancy in the last 5 years with the exception of the following:Other malignancies cured by surgery alone and having a continuous disease-free interval of 5 years are permitted. Cured basal cell carcinoma of the skin and cured in situ carcinoma of the uterine cervix are permitted.
- Any unstable systemic disease (including active infection, uncontrolled hypertension, unstable angina, congestive heart failure, myocardial infarction within the previous year, serious cardiac arrhythmia requiring medication, hepatic, renal, or metabolic disease).
- Eye inflammation or eye infection not fully treated or conditions predisposing the subject to this.
- Evidence of any other disease, neurological or metabolic dysfunction, physical examination or laboratory finding giving reasonable suspicion of a disease or condition that contraindicated the use of an investigational drug or puts the subject at high risk for treatment-related complications.
- Patient who has active serious infection (e.g. pyrexia of or 38.0℃ over)
- Patients who harbouring exon 20 T790M mutation.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: Synchronous therapy
'Gefitinib and Pemetrexed' Synchronous use of Gefitinib for 2 years during or after chemotherapy with Pemetrexed plus Cisplatin regimen.
Gefitinb, 250mg per day,take orally for 2 years.
Pemetrexed, 500mg/m2, day 1; Cisplatin 75mg/m2, day 1.
Three weeks as a cycle.
Four cycles in total.
|
Gefitinib 250mg per day for 2 years.
Outros nomes:
Pemetrexed, 500mg/m2, day 1; Cisplatin 75mg/m2, day 1.
Three weeks as a cycle.
Four cycles in total.
Outros nomes:
|
Comparador Ativo: Chemotherapy
Pemetrexed: Pemetrexed, 500mg/m2, day 1; Cisplatin 75mg/m2, day 1.
Three weeks as a cycle.
Four cycles in total.
|
Pemetrexed, 500mg/m2, day 1; Cisplatin 75mg/m2, day 1.
Three weeks as a cycle.
Four cycles in total.
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Disease free survival
Prazo: From date of randomization to the first documented disease progression or death, whichever occurs first, assessed up to 3 and 5 years.
|
To evaluate the disease free survival of synchronous therapy versus combination of Pemetrexed plus Cisplatin as adjuvant treatment for pathological stage II-IIIA(N1-N2) lung adenocarcinoma with EGFR mutation.Disease free survival (DFS)- defined as the time from randomization to the first documented disease progression or death, whichever occurs first.
|
From date of randomization to the first documented disease progression or death, whichever occurs first, assessed up to 3 and 5 years.
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Overall survival
Prazo: From date of randomization to the first documented death, assessed up to 5 years.
|
To evaluate the overall survival of synchronous therapy versus combination of Pemetrexed plus Cisplatin as adjuvant treatment for stage II-IIIA(N1-N2) lung adenocarcinoma with EGFR mutation.
|
From date of randomization to the first documented death, assessed up to 5 years.
|
Number of Participants with Adverse Events
Prazo: In the period of Gefitinib 250 mg/day oral daily for 24 months. Pemetrexed 500 mg/m2 intravenous infusion on day 1, Cisplatin 75 mg/m2 on day 1 for 4 cycles.
|
The safety and tolerability profile of gefitinib at a 250 mg daily dose relative to that of Chemotherapy.
|
In the period of Gefitinib 250 mg/day oral daily for 24 months. Pemetrexed 500 mg/m2 intravenous infusion on day 1, Cisplatin 75 mg/m2 on day 1 for 4 cycles.
|
Quality of life
Prazo: In the period of Gefitinib 250 mg/day oral daily for 24 months. Pemetrexed 500 mg/m2 intravenous infusion on day 1, Cisplatin 75 mg/m2 on day 1 for 4 cycles.
|
Quality of life as measured by the total score and Trial Outcome Index (TOI) of the Functional Assessment of Cancer Therapy - Lung Cancer (FACT-L) questionnaire.
|
In the period of Gefitinib 250 mg/day oral daily for 24 months. Pemetrexed 500 mg/m2 intravenous infusion on day 1, Cisplatin 75 mg/m2 on day 1 for 4 cycles.
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Li Xiaofei, MD, Tangdu Hospital of the Fourth Millitary Medical University
- Diretor de estudo: Yan Xiaolong, MD, Tangdu Hospital of the Fourth Millitary Medical University
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Antecipado)
Conclusão do estudo (Antecipado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças Respiratórias
- Neoplasias por Tipo Histológico
- Neoplasias
- Doenças pulmonares
- Neoplasias por local
- Carcinoma
- Neoplasias Glandulares e Epiteliais
- Neoplasias do Trato Respiratório
- Neoplasias Torácicas
- Neoplasias Pulmonares
- Adenocarcinoma
- Adenocarcinoma de Pulmão
- Mecanismos Moleculares de Ação Farmacológica
- Inibidores da Síntese de Ácido Nucleico
- Inibidores Enzimáticos
- Agentes Antineoplásicos
- Inibidores de proteína quinase
- Antagonistas do ácido fólico
- Gefitinibe
- Pemetrexede
Outros números de identificação do estudo
- W-TONG002
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Neoplasias Pulmonares
-
University of LorraineConcluídoCriança, Somente | Pneumotórax espontâneo | Pneumotórax idiopático | Bleb LungFrança
-
Assiut UniversityAinda não está recrutandoCâncer de pulmão | Lesão pulmonar | Bleb Lung
Ensaios clínicos em Gefitinib
-
Jiangsu Famous Medical Technology Co., Ltd.DesconhecidoCâncer de Pulmão de Células Não Pequenas
-
Sun Yat-sen UniversityDesconhecido
-
Sichuan Provincial People's HospitalDesconhecidoNSCL com mutação EGFR estágio IV com metástases cerebraisChina
-
Anhui Medical UniversityDesconhecidoAuto-eficácia | Toxicidade de MedicamentosChina
-
China Medical University, ChinaGeneral Hospital of Shenyang Military Region; Shengjing Hospital; Liaoning Tumor... e outros colaboradoresDesconhecidoCâncer de Pulmão de Células Não Pequenas
-
Samsung Medical CenterAstraZenecaDesconhecidoCâncer de Pulmão de Células Não Pequenas Positivo com Mutação EGFRRepublica da Coréia
-
Peking University Third HospitalDesconhecidoCâncer de Pulmão de Células Não PequenasChina
-
Tian XieLinkDoc Technology (Beijing) Co. Ltd.RecrutamentoAdenocarcinoma | Carcinoma | Câncer de Pulmão de Células Não PequenasChina